Case Reports of DRESS Syndrome and Symptoms Consistent with DRESS Syndrome Following Treatment with Recently Marketed Monoclonal Antibodies

Abstract EN

Background.

Monoclonal antibodies constitute a potent and broadly tolerable drug class, representing for some conditions the first newly approved treatment in years.

As such, many are afforded “fast-track” or “breakthrough therapy” designations by the U.S.

Food and Drug Administration, leading to provisional approval before Phase III clinical trials are reported.

Although these drugs are usually safe, some patients experience life-threatening complications—myositis and encephalitis have led to permanent or temporary recalls.

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a hypersensitivity condition easily missed due to its long incubation period and nonspecific presentation.

This minireview is primarily intended as an abbreviated guide for practitioners who may be using these powerful treatments.

Methodology.

We searched PubMed using a string of symptoms consistent with DRESS syndrome and monoclonal antibodies approved by the FDA since 2015.

Then, we excluded studies reporting dermatological complications of reactivation of nonherpetic infection, immunodeficiency-related infection, or reactions to the injection site or infusion.

We searched for and accessed prior reviews and background studies via PubMed, Mendeley, and Google Scholar.

Results.

Two cases of DRESS syndrome were identified in the literature, both the result of treatment with daclizumab.

There was one additional case of encephalitis without cutaneous symptoms caused by daclizumab.

Drug-induced hypersensitivity dermatitis was reported following treatment with nivolumab and two cases of combination treatment with ipilimumab and either nivolumab or durvalumab produced maculopapular rash and bullae in the first patient and lichenoid dermatitis and blisters in the second patient.

Conclusions.

Daclizumab was the only recently approved monoclonal antibody associated with DRESS syndrome as such.

Limitations in the diagnostic reliability of DRESS syndrome as a clinical entity and the lack of negative clinical trial reporting suggest enhanced vigilance on the part of clinicians and regulators may be warranted.